Monoclonal Antibodies Market for Colorectal Cancer to Witness Moderate Growth

The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase from $3.7 billion in 2012 to $5.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%, according to a new report from business intelligence providers Reportstack and  GBI Research. The company’s latest report Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth states that this moderate growth is due to the slow rise of the prevalent population and weakness of the late-stage pipeline. Currently, there is only one mAb product in Phase III development for the treatment of colorectal cancer, named IMC-1121B. Dominic Trewartha, Analyst for GBI Research says: “The efficacy of this drug has not yet been proven in large-scale, placebo-controlled Phase III trials, which creates an element of uncertainty in terms of the outcome of these products. As such, this weak late-stage pipeline is not expected to drive market growth to a significant extent during the forecast period.”

The current metastatic colorectal cancer market is dominated by three mAbs— Avastin, Erbitux and Vectibix — which are far more efficacious than the targeted small molecule therapies also marketed for this setting. Therefore, GBI Research believes there is a strong opportunity for the entry of new mAbs into the market, as long as they prove superior efficacy when compared to Avastin.  Trewartha says: “A product that can attain first-line status in the treatment of colorectal cancer, or even second-line status by displacing Erbitux and Vectibix, would have access to a considerable patient population and be able to generate a substantial amount of revenue.

“Furthermore, there are currently no approved mAbs in the early-stage setting for colorectal cancer, reflecting an additional opportunity for the development of new products,” the analyst concludes. More details and table of contents for this report can be found by visiting Monoclonal Antibodies Market for Colorectal Cancer report.

Similar Reports on Monoclonal Antibodies Market:

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion

Global Monoclonal Antibodies Market 2011-2015

Contact:
Debora White
contactus@reportstack.com
Naperville
Illinois
United States
Ph: +1-888-789-6604

###